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Abstract
 .Treatment of M1 myeloid leukemia cells with leukemia inhibitory factor LIF causes activation of transcription factors
 .Stat1, Stat3 and Stat5a signal transducers and activators of transcription . DNA-binding of Stat proteins was detectable for
extended periods of time in LIF-treated M1 cells, which simultaneously underwent terminal differentiation. The relative
composition of Stat factors in the protein–DNA complexes changed during time. Whereas Stat3 was activated up to 36 h
during treatment with LIF, Stat5a was activated only short-termed. Similarly, high expression of the immediate early gene
 .CIS cytokine-inducible SH2-containing protein , a known target gene of Stat5 in hematopoietic cells, occurred only during
the onset of differentiation. This suggests a role of Stat5a in the early phase of LIF-induced differentiation and growth arrest
of M1 cells. q 1998 Elsevier Science B.V.
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1. Introduction
 .The cytokine leukemia inhibitory factor LIF ex-
erts pleiotropic effects on a variety of target cells.
One of its characteristic features, from which the
name was derived, is its ability to induce differentia-
Abbreviations: a M, a -macroglobulin; CIS, cytokine-in-2 2
ducible SH2-containing protein; EMSA, electrophoretic mobility
shift assay; GAPDH, glyceraldehyde-3X-phosphate dehydroge-
nase; IL-6, Interleukin-6; Jak, Janus kinase; LIF, leukemia in-
hibitory factor; MGF, mammary gland factor; PCBA, proteolytic
clipping bandshift assay; RE, response element; SSI-1, Stat-in-
duced Stat inhibitor-1; SOCS-1, suppressor of cytokine sig-
nalling-1; Stat, signal transducers and activators of transcription
) Corresponding author. Fax: q49-9131-85-85-26; E-mail:
ghocke@biologie.uni.erlangen.de
tion and growth arrest in M1 cells, a myelomonocytic
w xleukemia-derived cell line 1 . M1 cells offer a suit-
able model system to study the molecular mecha-
nisms of LIF-induced terminal differentiation and
growth arrest of myeloid leukemia cells.
 .LIF belongs to the family of Interleukin-6- IL-6
type cytokines which utilize a common signal path-
w xway 2 . It involves tyrosine protein kinases of the
 .family of Janus kinases Jak and transcription factors
of the family of signal transducers and activators of
 .transcription Stat , the so called JakrStat pathway
w x3,4 . After binding of the cytokine to its specific
ligand-binding chain, the ligand–receptor complexes
couple to the common signal transducer subunit
gp130, thus, activating it in turn. This event leads to
the activation of receptor associated Jak kinases which
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phosphorylate cytoplasmic Stat factors at specific
tyrosine residues. As a consequence, Stat factors
dimerize and translocate to the nucleus to bind to
specific DNA response elements in the transcriptional
w xcontrol regions of their respective target genes 3,4 .
Incubation of various cell types with LIF leads
w xmainly to the activation of Stat proteins 1 and 3 5,6 .
However, nuclear extracts of M1 cells contained
w xactivated Stat5a in addition 7,8 . Stat factors bound
 .to response elements RE from various target genes
w x9 such as the LIF-RE of the rat a -macroglobulin2
 . w xa M gene 10,11 . A characteristic protein–DNA2
complex, referred to as complex II, was assembled
between the LIF-RE and nuclear proteins from vari-
ous cell types after incubation of the cells with LIF
w x6,7,10 .
Differentiation and growth arrest of M1 cells were
w xstrictly dependent on activated Stat3 12,13 , but not
w xStat1 13 . These results demonstrated a critical and
causative role of the JakrStat signalling pathway in
the induction of differentiation of M1 cells. However,
a possible involvement of Stat5a was not addressed.
 .Stat5arMGF mammary gland factor was initially
discovered as a prolactin-activated Stat factor in sheep
w xmammary gland epithelial cells 14 . In contrast to
other known Stat factors, Stat5 occurs in two forms,
Stat5a and Stat5b, and two species of genes coding
w xfor Stat5 have been cloned 15–18 . Stat5 proteins
are activated in different cell types including hemato-
poietic and epithelial cells by a variety of different
peptide hormones, cytokines and hematopoietic
w xgrowth factors 19 .
Recently, we demonstrated that treatment of the
myeloid leukemic cell line M1 with LIF led to activa-
w xtion of Stat5a in addition to Stat1 and Stat3 7 . Here
the special properties of activation of Stat5a com-
pared to Stat3 were analyzed. Our findings suggest a
certain role of Stat5a in the early phase of induction
of differentiation of LIF-treated M1 cells.
2. Materials and methods
2.1. Cell culture and reagents
M1 murine myelomonocytic cells American Type
.Culture Collection were grown in RPMI medium
supplemented with 10% fetal calf serum Boehringer
.Ingelheim, Heidelberg, Germany , 2 mM L-gluta-
mine, 100 unitsrml penicillin and 100 mgrml
streptomycin. The supernatant of a stably transfected
CHO cell line secreting recombinant human LIF
 .Genetics Institute, Cambridge, MA was used as a
source of human LIF at a final dilution of 1:100.
2.2. Preparation of protein extracts
Nuclear and cytoplasmatic protein extracts were
w xprepared according to published procedures 20,21 .
Briefly, after homogenization of the cells and pellet-
ing of the nuclei, cytosolic extracts were obtained.
The supernatant was cleared by centrifugation
 .14 000=g for 10 min at 48C and cytoplasmatic
proteins were precipitated with ammonium sulfate.
Proteins from the nuclei were extracted under high
 .salt conditions 0.42 M NaCl and concentrated by
precipitation with ammonium sulfate. Extraction
buffers were supplemented with 0.5 mM phenyl-
 .methyl-sulfonylfluoride PMSF and 100 kallikrein-
 . inhibitory KI unitsrml of aprotinin Roth, Karls-
.ruhe, Germany .
Whole cell extracts were prepared essentially as
w xdescribed 22 . The extraction buffer was supple-
mented with 3 mgrml aprotinin, 1 mM PMSF, 7
mgrml leupeptin, 1 mgrml pepstatin and 1 mM
sodium orthovanadate. Protein concentrations were
determined using the colorimetric assay of Bradford
w x23 .
( )2.3. Electrophoretic mobility shift assay EMSA
EMSA was performed following published proce-
w xdures 24 . Binding reactions were carried out for 20
min at 258C in a 20 ml reaction volume containing 10
mM HEPES, 50 mM KCl, 0.1 mM EDTA, 1 mM
dithiothreitol, 6 mM MgCl , 1.2 mM CaCl , 2 KI2 2
 .units of aprotinin, 2.5 mg of poly dI:dC , 2.5 mg of
single-stranded salmon sperm DNA, 10% glycerol,
variable amounts of nuclear protein and approxi-
mately 7 fmol of the double-stranded, 32P-labelled
oligonucleotide TB2. This probe was end-labelled
with polynucleotide kinase and used at a specific
activity of f3=106 cpmrpmol, corresponding to
2=104 cpm per reaction. TB2 included two copies
of the core-element of the IL-6-response element
 .IL-6-RE from the rat a -macroglobulin gene which2
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 Xa ls o a c ts a s a L IF -R E T B 2 : 5 -
GATCATCCTTCTGGGAATTCTGATATCC
TTCTGGGAATTCTG-3X; Stat binding sequence un -
. w xderlined 10,20,25 . Its sequence represents a bind-
ing site for Stat3 and resembles the prolactin re-
sponse element of the b-casein promoter, a binding
site for Stat5, and the so called g-activating-site, a
binding site for Stat1.
EMSA-competition analysis was performed with a
100-fold molar excess of double-stranded oligo-
nucleotides representing wild type or mutant se-
w xquences of the LIF-RE 20,25 .
EMSA-supershift assays were performed by prein-
cubation of extracts with antibodies for 1 h at 48C
prior to DNA-binding. The following antibodies were
used: mouse antibodies directed against the C-termi-
nal part of human Stat1a from Dr. J.E. Darnell,
.New York, NY ; rabbit antibodies against the C-
terminal part of murine Stat3 C-20; Santa Cruz
.Biotechnology, Heidelberg, Germany ; chicken anti-
bodies against the N-terminus of ovine Stat5arMGF
w x14,17 ; and appropriate control antibodies.
( )2.4. Proteolytic clipping bandshift assay PCBA
 .Constant amounts of nuclear protein extract 5 mg
were incubated with the 32P-labelled probe TB2 for
10 min as described above. Thereafter increasing
amounts of proteinase type XVII from Staphylococ-
 .cus aureus V8 Sigma, Deisenhofen, Germany were
added and the reaction mixture was incubated for
w xanother 10 min at 378C 26 . Proteolytic fragments
were analyzed by electrophoresis in a 5% polyacryl-
amide gel and visualized by autoradiography.
2.5. Immunoprecipitation and Western blotting
Stat3 was immunoprecipitated from whole cell
extracts using antibody C-20. Stat5a was precipitated
using a polyclonal rabbit anti-peptide serum raised
against the C-terminal part of murine Stat5a AA
.774–793 . Immune complexes were collected by in-
cubation with protein A–agarose, washed and ana-
lyzed by SDS-PAGE and Western blotting. Signals
were visualized using an enhanced chemiluminescent
 .system Amersham, Braunschweig, Germany . Anti-
 .bodies against phosphotyrosine pY20 were obtained
from Santa Cruz Biotechnology.
2.6. RNA extraction and Northern blot analysis
RNA was isolated by the guanidine isothio-
w x  .qcyanate–cesium chloride method 27 . Poly A -en-
riched RNA was purified on oligo-dT-cellulose. Three
 .qmg of poly A -enriched RNA per sample was sepa-
rated by 1% agarose–formaldehyde gels, transferred
 .to Hybond N-membranes Amersham and fixed by
UV-crosslinking. Prehybridization was performed in
50% formamider5=SSC 1=SSC is 150 mM
.sodium chlorider15 mM sodium citrate r1% SDSr2
=Denhardt’s 1=Denhardt’s is 20 mgrml each of
polyvinylpyrrolidonerFicoll 400rbovine serum albu-
.min at 428C. Filters were hybridized with 50 ng of
32P-labelled cDNA fragments overnight. Probes were
w 32 x  .radiolabelled with a P dCTP Amersham to spe-
cific activities of 2–6=108 cpmrmg DNA using a
 .commercial kit Pharmacia, Freiburg, Germany .
cDNA fragments for murine Stat1 nucleotides 1835
w x. to 2228; Ref. 28 , Stat3 nucleotides 479 to 997;
w x. Ref. 5 and Stat5a nucleotides 1192 to 1717; Ref.
w x.14,16 were generated by reverse transcriptase–
 .polymerase chain reaction RT–PCR using RNA
from M1 cells and the following primers: Stat1, sense
 . X XS : 5 -GCCATCACATTCACATGGG-3 , antisense
 .Fig. 1. The protein–DNA complex II II stays detectable in
LIF-treated M1 cells for several hours without a major decrease
 .in intensity. A Nuclear proteins from M1 cells treated with LIF
for the indicated lengths of time were prepared and EMSA
 .experiments were performed. B Nuclear proteins of M1 cells
 .  .  .treated with LIF for 3 h track 1 , 8 h track 2 , 10 h track 3 and
 .36 h track 4 were analyzed in EMSA experiments.
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 . X X  .AS : 5 -CTACAGAGCCCACTATCCG-3 ; Stat3 S :
X X  . X5 -GACAGAGAAGCAGCAGATG-3 , AS : 5 -
X  . XACGATCCTCTCCTCCAGC-3 ; and Stat5 S : 5 -
X  . XAACAACTGCTGCGTGrCATGGA-3 , AS : 5 -
ACTGCCAGAAGGTArGTAArGTTC-3X. Hy-
bridization with a radiolabeled 0.8 kb Pst I cDNA
 Xfragment of rat GAPDH glyceraldehyde-3 -phos-
. w xphate dehydrogenase 29 was used as loading con-
trol. An EcoRI–NotI murine cDNA fragment was
used as a CIS cytokine-inducible SH2-containing
. w xprotein -specific hybridization probe 30 . Filters were
washed with high stringency and autoradiographs
were evaluated using a laser densitometer
 .Pharmacia .
3. Results
3.1. DNA-binding of Stat proteins stays detectable for
a prolonged time after treatment of M1 cells with LIF
The LIF-RE of the a M-gene represents a binding2
site for Stat3 and resembles bindings sites for Stat5
and Stat1. Using a dimer of its binding site as a probe
 .TB2 , a characteristic gel mobility shift complex,
complex II, was formed with nuclear proteins from
M1 cells after incubation of the cells with LIF. This
protein–DNA complex contained Stat1, Stat3 and
w xStat5a, but not Stat5b 7 . As Stat5b was not con-
tained in complex II, further studies focused on Stat5a.
DNA-binding of Stat factors occurred rapidly and
intensities of complex formation stayed unchanged
 w x.for up to 6 h Fig. 1A and Ref. 31 . Activation of
Stat factors was detectable for an extended period of
 .time Fig. 1B . After 2 days of treatment with LIF,
when differentiation already was detectable, complex
II was still formed R. Piekorz and G. Hocke, unpub-
.lished results .
3.2. The le˝els of Stat mRNAs, but not of Stat
proteins, increase in M1 cells after treatment with
LIF
mRNAs for Stat1, Stat3 and Stat5 were already
 .present in untreated M1 cells Fig. 2A . Three differ-
 .ent variants of Stat1 mRNA 4.1, 3.4 and 2.9 kb and
 .two variants of Stat5 mRNA 4.6 and 3.7 kb most
w xlikely representing Stat5b and Stat5a 17 , respec-
tively, were detected as well as one species of Stat3
 .mRNA 4.3 kb . After addition of LIF, the concentra-
tion of mRNAs of all three Stat factors increased.
Maximum levels were reached after 4 h of LIF-treat-
ment of M1 cells for Stat1 and after 2 h for Stat3 and
 .Stat5 Fig. 2B . At later times, the concentrations
decreased, but remained higher during the entire pe-
riod of observation compared to the initial values
 .Fig. 2A,B . The relative increases were approxi-
mately 16-fold for Stat3 and 5- to 6-fold for Stat1.
The 4.6 kb mRNA for Stat5b increased only 1.5-fold,
but the 3.7 kb species coding for Stat5a increased
4-fold. Despite of the different amounts of Stat mRNA
the concentrations of Stat proteins did not change
significantly during treatment of the cells with LIF
 .Fig. 2C . The increased intensities seen in the West-
ern blot experiment were due to unequal loading,
demonstrated by incubation of the membrane with
antibodies against b-actin Hocke, unpublished re-
.sult . As the intensities of complex II did not vary
significantly during time of cytokine treatment, the
features of the proteins contained in complex II of
 .Fig. 2. The concentrations of mRNAs but not proteins for Stat1, Stat3 and Stat5 increase after treatment of M1 cells with LIF. A
Concentration of mRNAs for Stat1, Stat3 and Stat5 increase after treatment of M1 cells with LIF. Northern blots were prepared using
 .q  .poly A -RNA from M1 cells incubated with LIF for increasing lengths of time as indicated . Specific cDNA fragments for murine
 .Stat1, Stat3 and Stat5 were used as hybridization probes as described in Section 2. Hybridization with a cDNA probe for GAPDH was
 .performed as loading control. B Intensities of mRNAs were evaluated by laser densitometry of autoradiographs and corrected for
constant loading by normalization to the GAPDH signals. Relative intensities are the ratios of the signals from LIF-treated M1 cells
divided by the corresponding signals from untreated cells. The result for the mRNA species for Stat1 are presented in the top panel: black
bar: 4.1 kb; dotted bar: 3.4 kb; striped bar: 2.9 kb; center panel: 4.3 kb mRNA for Stat3; bottom panel presents the mRNA species for
 .Stat5: striped bar: 4.6 kb; dotted bar: 3.7 kb. C Amounts of Stat1, Stat3 and Stat5 stay constant after treatment of M1 cells with LIF.
Cell extracts were prepared from M1 cells treated with LIF for the indicated times. A total of 30 mg protein per lane was separated by
SDS-polyacrylamide gel electrophoresis and blotted to a nitrocellulose membrane. Western blotting was performed using antibodies
specific for the indicated Stat proteins.
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differentiating M1 cells were investigated in greater
detail.
3.3. The quantitati˝e composition of Stat factors of
complex II changes in M1 cells with increasing time
of incubation with LIF
Nuclear extracts from M1 cells treated with LIF
for 15 min and 4 h, referred to as ‘early’ and ‘late’
extracts, respectively, were compared in gel mobility
shift experiments after preincubated with a protease
 .Fig. 3A . This proteolytic clipping bandshift assay
 .PCBA produced three blocks of proteolytic frag-
 .ments marked a, b and c in Fig. 3A . The fragments
of group ‘a’ retained sequence-specificity for the
LIF-RE as determined by competition gel-mobility
 .shift analysis Fig. 3B . The intensity of the faster
migrating subset of proteolytic fragments of group ‘a’
was clearly reduced in the ‘late’ nuclear extracts Fig.
.3B, tracks 8–13 . The ‘late’ complex II contained
proteins reacting in a different manner to proteolytic
clipping than the ‘early’ complex II probably due to
different relative amounts or biochemical differences
of the proteins. Simultaneously, the dependence of
the formation of complex II on protein synthesis
changed. Whereas the ‘early’ activation of Stat pro-
teins was independent of protein synthesis, the ap-
pearance of the ‘late’ complex II was prevented by
continuous treatment of the cells with cycloheximide
 .R. Piekorz and G. Hocke, unpublished observations .
Therefore, although the intensity of complex II did
Fig. 3. Proteins of complex II display a different proteolytic
sensitivity depending on the length of treatment of the cells with
 .LIF. A Nuclear extracts of M1 cells incubated with LIF for 15
 .  .min tracks 2–7 or 4 h tracks 8–13 were used. Constant
 .amounts 5 mg of nuclear proteins were incubated with increas-
ing amounts of V8 proteinase for 10 min. Thereafter EMSA
 .  .experiments were performed. Tracks: 1 without protein; 2, 8
 .  .no proteinase; 3–7 and 9–13 2.5, 5, 10, 20 and 30 mg of V8
proteinase, respectively. a, b, c: regions of proteolytic fragments;
 .F: free probe. B Proteolytic fragments of region ‘a’ bind
sequence-specific to the Stat binding site. PCBA was performed
with nuclear extracts from LIF-treated M1 cells as outlined in
 .  .track 5 of A . The binding reactions contained: 1 no competi-
 .tor; 2 100-fold excess of unlabelled double-stranded wild type
w x  .oligonucleotide 20,25 ; 3 100-fold excess of the mutant oligo-
w xnucleotide 20,25 II: complex II; a, b, c: regions of proteolytic
fragments; F: free probe.
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not change to a great extent during treatment with
 .LIF Fig. 1A,B the biochemical features of factors
binding to the LIF-RE varied during time. Conse-
quently, we investigated the composition of complex
II.
Nuclear extracts from M1 cells from ‘early’ and
‘late’ time points after LIF-treatment were compared
in EMSA experiments using Stat-specific antibodies.
Incubation with anti-Stat1a , anti-Stat3 and anti-Stat5a
antisera revealed the presence of these Stat factors in
 .both extracts Fig. 4A . However, the reactivity of
‘late’ nuclear extracts with anti-Stat1a and anti-
Stat5a antisera was less pronounced compared to the
‘early’ extracts Fig. 4A, left and right panel, tracks 3
.and 6 . At the same time, the reactivity with anti-Stat3
antiserum was increased. Complex II assembled with
nuclear extracts of M1 cells treated with LIF for 36 h
contained no Stat1 and Stat5a, but only Stat3 Fig.
.4B . In summary, although the intensity of complex
II did not change to a great extent during treatment
 .with LIF Fig. 1 the composition of Stat proteins
binding to the LIF-RE varied significantly during
time.
 .Fig. 4. The amounts of Stat factors contained in complex II II
 .vary during LIF-treatment of M1 cells. A Nuclear extracts from
 .  .M1 cells treated with LIF for 15 min 1–3 or 4 h 4–6 were
 .preincubated with control antibodies 2, 5 or specific antibodies
 . against Stat1a , Stat3 or Stat5a 3, 6 and analyzed by EMSA. 1,
.  .4 without antibody treatment. B Nuclear extracts of M1 cells
 .  .treated with LIF for 36 h were analyzed as in A : 1 without
 .antibody treatment; 2–5 after preincubation with antibodies
 .  .  .against Stat1a 2 , Stat3 3 , Stat5a 4 and control antibodies
 .5 . S: supershifted complexes.
 .  .Fig. 5. Stat3 A and Stat5a B show different kinetics of
tyrosine phosphorylation during treatment of M1 cells with LIF.
 .Stat factors were immunoprecipitated IP from M1 cells and
analyzed by Western blotting using anti-phosphotyrosine a-P-
.Tyr and Stat-specific antibodies as indicated. IgH: Immunoglob-
ulin heavy chains.
3.4. The kinetics of the acti˝ation status of Stat5a
differs compared to Stat3
A parallel development of the tyrosine phosphory-
lation status of Stat3 and Stat5a in time was observed
compared to the activation measured by specific
 .binding to DNA Fig. 4 . Stat3 remained tyrosine
 .phosphorylated at least up to 36 h Fig. 5A , whereas
Stat5a was phosphorylated only short-termed after
treatment with LIF. After 30 min, a strong signal was
visible which decreased completely during the next 6
h, although the amount of Stat5a stayed constant
 .Fig. 5B . The different course of phosphorylation of
Stat3 and Stat5a explains the change in composition
of the characteristic protein–DNA complexes demon-
strated in Fig. 4.
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Fig. 6. Immediate early expression of mRNAs for CIS in M1
cells treated with LIF for increasing lengths of time. Hybridiza-
tion with a GAPDH probe was used as loading control.
3.5. Expression of the immediate early gene CIS
parallels the acti˝ation status of Stat5a
Northern blot analysis revealed that the mRNA for
CIS was hardly detectable in proliferating M1 cells,
but the expression increased enormously already 30
min after incubation of the cells with LIF. Maximal
mRNA levels were reached after 1 h, demonstrating
that CIS behaves as an immediate early gene in
 .LIF-treated M1 cells Fig. 6 . In accordance with
w xYoshimura et al. 30 two mRNA species were found,
a major transcript of 2.0 kb and a minor transcript of
4.4 kb. The amount of CIS mRNAs declined during
time and after 24 h of treatment of the cells with LIF
the concentration of CIS transcripts was clearly re-
duced and declined even thereafter. The kinetics of
the levels of mRNAs for CIS apparently followed the
 .activation status of Stat5a in M1 cells Fig. 5B .
4. Discussion
The main conclusions drawn from the presented
data were the following.
 .1 The formation of a characteristic protein–DNA
complex, complex II, remained detectable for ex-
tended periods of time after treatment of M1 myeloid
leukemia cells with LIF and correlated with the dif-
ferentiation process of the cells.
 .2 During treatment of M1 cells with LIF the
mRNA levels of Stat factors increased, whereas the
corresponding protein concentration did not change
significantly.
 .3 The composition of Stat factors present in
complex II changed during treatment of M1 cells
with LIF. The amounts of Stat1 and Stat5a decreased
during time and after 36 h of LIF-treatment only
Stat3 was detectable in the protein–DNA complex.
 .4 The course of tyrosine phosphorylation of Stat3
and Stat5a induced by treatment of M1 cells with LIF
differed greatly. Whereas Stat5a was activated only
during the first 6 h, phosphorylation of Stat3 stayed
detectable at least up to 36 h.
 .5 CIS, a known target gene for Stat5, was ex-
pressed as an immediate early gene in LIF-treated
M1 cells and its expression level apparently followed
the activation status of Stat5a.
The critical role of the JakrStat signalling path-
way in terminal differentiation and growth arrest of
M1 cells was recently established. After activation
and function of Stat3 were prevented, cytokine-treated
w xM1 cells failed to undergo differentiation 12,13 . In
addition, differentiation was blocked in M1 cells
 .overexpressing a Stat-induced Stat inhibitor SSI-1 ,
also called SOCS-1 suppressor of cytokine sig-
. w xnalling-1 32,33 . This inhibitor was capable of bind-
ing to activated Jak kinases, thereby reducing the
amounts of tyrosine-phosphorylated gp130 and Stat3.
These findings demonstrated that the level of activa-
tion of Stat factors was not only controlled by Jak
kinases but also by inhibitors of the JakrStat signal
pathway.
The formation of the protein–DNA complex II in
cytokine-treated M1 cells was not transient but re-
mained elevated for extended periods of time Fig. 1
w x.and Ref. 31 . This result was rather unexpected,
since the formation of complex II was clearly de-
creased in other cell types during treatment with LIF,
such as embryonic stem cells and HepG2 hepatoma
 w x .cells Ref. 6 and G. Hocke, unpublished data . In
particular, this downregulation was influenced by the
activity of one or more tyrosine phosphatases. Inter-
estingly, dephosphorylation was also involved in the
regulation of the amounts of activated Stat factors in
LIF-treated M1 cells, because inhibition of tyrosine
phosphatases by treatment of the cells with ortho-
vanadate caused an increase in the levels of phospho-
rylated Stat3 and Stat5a R. Piekorz and G. Hocke,
.unpublished observation . However, the amounts of
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activated phosphatases and probably also of the Jak-
w xinhibitor SSI-1rSOCS-1 32,33 might be to low to
lead to a complete decrease of the intensity of com-
 .plex II in cytokine-treated M1 cells Fig. 1 .
Despite of the sustained formation of complex II in
M1 cells, the composition of Stat factors binding to
the LIF-RE changed with time. A difference between
the composition of proteins binding to the LIF-RE
‘early’ and ‘late’ after treatment with LIF was ob-
 .served in PCBA experiments Fig. 3 . These differ-
ences could either be due to different proteolytic
sensitivities of the DNA-binding proteins caused by
biochemical differences or a variation of the compo-
sition of Stat factors contained in complex II. The
amounts of Stat1 and Stat5a present in complex II
were diminished, whereas the contribution of Stat3
increased and at later time points only activated Stat3
 .was detectable Figs. 4 and 5A . This activation
course of Stat3 explained the kinetics of expression
w xof junB, a target gene of Stat3 9,34 and a character-
w xistic marker of myeloid leukemic differentiation 35 .
Expression of junB started immediate early after
exposure of M1 cells to LIF and stayed high during
the whole differentiation process. In contrast to these
findings, the kinetics of expression of CIS, a target
w xgene of Stat5 36,37 , was different. Transcription of
CIS was induced immediate early after treatment of
M1 cells with LIF and maximal amounts of CIS
mRNAs were observed after 1 h Fig. 6 and Ref.
w x. w x33 . In contrast to junB 35 the levels of CIS
mRNAs declined after prolonged cytokine treatment
 .Fig. 6 . The amount of the 4.4 kb species decreases
rapidly already after 2 h, whereas the amount of the
2.0 kb species was high up to 12 h but declined
strongly thereafter. Therefore, the kinetics or expres-
sion of CIS matches better the activation status of
Stat5a then of Stat3. We currently cannot exclude
that other factors might influence the expression of
CIS during differentiation of M1 cells. Nevertheless,
different reports have clearly shown that activation of
Stat5 is crucial for expression of CIS in hemato-
w xpoietic cells 37,38 and, thus, the situation might be
similar in the myelomonocytic cell line M1. To
demonstrate a major involvement of Stat5a its func-
tion needs to be inhibited by overexpression of a
dominant negative mutant of Stat5a in M1 cells and,
thus, should lead to impaired expression of CIS.
Here, we demonstrated in LIF stimulated M1 cells
that a target gene for Stat5 was activated and, thus,
Stat5 seems to be involved in the modulation of gene
expression during the onset of differentiation.
Interestingly, Stat5a was associated with terminal
differentiation of human U-937 myeloid leukemia
cells and primary chicken myeloid progenitor cells
w x39,40 . On the other hand, murine myeloid leukemic
cell lines unresponsive to IL-6-type cytokines dis-
played various defects in the JakrStat signalling
pathway. Especially expression, activation and bind-
ing of Stat5a to the LIF-RE were altered in various
w xlines compared to M1 cells 41 . Although Stat5a-de-
ficient mice displayed a normal process of hemato-
w xpoiesis 42 recent data demonstrate that Stat5 was
w xrequired for erythroleukemic differentiation 38 . In
summary, our data and the findings from others
indicate a function of Stat5 in the differentiation of
leukemic cells.
Acknowledgements
Gifts of anti-Stat1a antibodies from Dr. J.E. Dar-
. nell, Jr., New York , the CHO-LIF cell line from
.Genetics Institute, Cambridge, MA and the CIS
 .probe from A. Miyajima, Tokyo are gratefully ac-
knowledged. Especial thanks to Dr. G. Fey for criti-
cal discussion. This work was supported by research
 .grant Deutsche Forschungsgemeinschaft DFG Hi
291r5-5 TP6 and by the Wilhem Sander-Stiftung
awarded to G.M.H.
References
w x1 D.J. Hilton, LIF: lots of interesting functions, TIBS 17
 .1992 72–76.
w x2 T. Kishimoto, S. Akira, M. Narazaki, T. Taga, Interleukin-6
 .family of cytokines and gp130, Blood 86 1995 1243–1254.
w x3 J.E. Darnell, I.M. Kerr, G.R. Stark, Jak–Stat pathways and
transcriptional activation in response to IFNs and other
 .extracellular signalling proteins, Science 264 1994 1415–
1421.
w x4 J.N. Ihle, I.M. Kerr, Jaks and Stats in signalling by the
 .cytokine receptor superfamily, TIG 11 1995 69–74.
w x5 S. Akira, Y. Nishio, M. Inoue, X.-J. Wang, S. Wei, T.
Matsusaka, K. Yoshida, T. Sudo, M. Naruto, T. Kishimoto,
Molecular cloning of APRF, a novel IFN-stimulated gene
factor 3 p91-related transcription factor involved in the
 .gp130-mediated signalling pathway, Cell 77 1994 63–71.
( )R.P. Piekorz et al.rBiochimica et Biophysica Acta 1402 1998 313–323322
w x6 G.M. Hocke, M.-Z. Cui, G.H. Fey, The LIF response ele-
ment of the a -macroglobulin gene confers LIF-induced2
transcriptional activation in embryonal stem cells, Cytokine
 .7 1995 491–502.
w x7 R.P. Piekorz, C. Nemetz, G.M. Hocke, Members of the
family of IL-6-type cytokines activate Stat5a in various cell
 .types, Biochem. Biophys. Res. Commun. 236 1997 438–
443.
w x8 R. Starr, U. Novak, T.A. Willson, M. Inglese, V. Murphy,
W.S. Alexander, D. Metcalf, N.A. Nicola, D.J. Hilton, M.
Ernst, Distinct roles for leukemia inhibitory factor receptor
a-chain and gp130 in cell type-specific signal transduction,
 .J. Biol. Chem. 272 1997 19982–19986.
w x9 J. Yuan, U.M. Wegenda, C. Lutticken, J. Buschmann, T.¨
Decker, C. Schindler, P.C. Heinrich, F. Horn, The signalling
pathways of interleukin-6 and g-interferon converge by the
activation of different transcription factors which bind to
common responsive DNA elements, Mol. Cell. Biol. 14
 .1994 1657–1668.
w x10 G.M. Hocke, M.-Z. Cui, J.A. Ripperger, G.H. Fey, Regula-
tion of the rat a -macroglobulin gene by interleukin-6 and2
leukemia inhibitory factor, in: A. Mackiewicz, I. Kushner,
 .H. Baumann Eds. , Acute Phase Proteins: Molecular Biol-
ogy, Biochemistry, Clinical Applications, CRC Press, Boca
Raton, FL, 1993, pp. 467–494.
w x11 C.-F. Lai, J. Ripperger, K. Morella, Y. Wang, D. Gearing,
N.D. Horseman, S.P. Campos, G.H. Fey, H. Baumann, Stat3
and Stat5b are targets of two different signal pathways
activated by hematopoietin receptors and control transcrip-
tion via separate cytokine response elements, J. Biol. Chem.
 .270 1995 23254–23257.
w x12 M. Minami, M. Inoue, S. Wei, K. Takeda, M. Matsumoto,
T. Kishimoto, S. Akira, Stat3 activation is a critical step in
gp130-mediated terminal differentiation and growth arrest of
 .a myeloid cell line, Proc. Natl. Acad. Sci. U.S.A. 93 1996
3963–3966.
w x13 K. Nakajima, K. Yamanaka, H. Kojima, M. Ichiba, N.
Kiuchi, T. Kitaoka, T. Fukada, M. Hibi, T. Hirano, A
central role for Stat3 in IL-6-induced regulation of growth
and differentiation in M1 leukemia cells, EMBO J. 15
 .1996 3651–3658.
w x14 H. Wakao, F. Gouilleux, B. Groner, Mammary gland factor
 .MGF is a novel member of the cytokine regulated tran-
scription factor gene family and confers the prolactin re-
 .sponse, EMBO J. 13 1994 2182–2191.
w x15 M. Azam, H. Erdjument-Bromage, B.L. Kreider, M. Xia, F.
Quelle, R. Basu, C. Saris, P. Tempst, J.N. Ihle, C. Schindler,
Interleukin-3 signals through multiple isoforms of Stat5,
 .EMBO J. 14 1995 1402–1411.
w x16 A.L.-F. Mui, H. Wakao, A.-M. O’Farrell, N. Harada, A.
Miyajima, Interleukin-3, granulocyte–macrophage colony
stimulating factor and interleukin-5 transduce signals through
 .two Stat5 homologues, EMBO J. 14 1995 1166–1175.
w x17 X. Liu, G.W. Robinson, F. Gouilleux, B. Groner, L. Hen-
nighausen, Cloning and expression of Stat5 and an addi-
 .tional homologue Stat5b involved in prolactin signal trans-
duction in mouse mammary tissue, Proc. Natl. Acad. Sci.
 .U.S.A. 92 1995 8831–8835.
w x18 J.A. Ripperger, S. Fritz, K. Richter, G.M. Hocke, F.
Lottspeich, G.H. Fey, Transcription factors Stat3 and Stat5b
are present in rat liver nuclei late in an acute phase response
and bind interleukin-6 response elements, J. Biol. Chem.
 .270 1995 29998–30006.
w x19 J.N. Ihle, Signalling by the cytokine receptor superfamily in
normal and transformed hematopoietic cells, Adv. Cancer
 .Res. 68 1996 23–65.
w x20 G.M. Hocke, D. Barry, G.H. Fey, Synergistic action of
interleukin-6 and glucocorticoids is mediated by the inter-
leukin-6 response element of the rat a -macroglobulin gene,2
 .Mol. Cell. Biol. 12 1992 2282–2294.
w x21 D.J. Shapiro, P.A. Sharp, W.W. Wahli, M.J. Keller, A
high-efficiency HeLa nuclear transcription extract, DNA 7
 .1988 47–55.
w x22 A. Eilers, D. Georgellis, B. Klose, C. Schindler, A.
Ziemiecki, A.G. Harpur, A.F. Wilks, T. Decker, Differentia-
tion-regulated serine phosphorylation of Stat1 promotes GAF
 .activation in macrophages, Mol. Cell. Biol. 15 1995 3579–
3586.
w x23 M. Bradford, A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the princi-
 .ple of protein–dye binding, Anal. Biochem. 72 1976 248–
254.
w x24 M. Fried, D.M. Crothers, Equilibria and kinetics of lac
repressor–operator interactions by polyacrylamide gel elec-
 .trophoresis, Nucleic Acids Res. 9 1981 6505–6525.
w x25 T. Brechner, G. Hocke, A. Goel, G.H. Fey, Interleukin-6
response factor binds cooperatively at two adjacent sites in
the promoter upstream region of the rat a -macroglobulin2
 .gene, Mol. Biol. Med. 8 1991 267–285.
w x26 E. Schreiber, P. Matthias, M.M. Muller, W. Schaffner,¨
Identification of a novel lymphoid specific octamer binding
 .protein OTF-2B by proteolytic clipping bandshift assay
 .  .PCBA , EMBO J. 7 1988 4221–4229.
w x27 J. Sambrook, E.F. Fritsch, T. Maniatis, Molecular Cloning:
A Laboratory Manual, Cold Spring Harbour Laboratory,
Cold Spring Harbour, NY, 1989.
w x28 X.-Y. Fu, A transcription factor with SH2 and SH3 domains
is directly activated by an interferon-a-induced cytoplas-
 .  .matic protein tyrosine kinase s , Cell 70 1992 323–335.
w x29 P. Fort, L. Marty, M. Piechaczyk, S. ElSabrouty, C. Dani, P.
Jeanteru, J.M. Blanchard, Various rat adult tissues express
only one major mRNA species from the glyceraldehyde-3-
 .phosphate dehydrogenase, Nucleic Acids Res. 13 1985
1431–1441.
w x30 A. Yoshimura, T. Ohkubo, T. Kiguchi, N.A. Jenkins, D.J.
Gilbert, N.G. Copeland, T. Hara, A. Miyajima, A novel
cytokine-inducible gene CIS encodes an SH2-containing
protein that binds to tyrosine-phosphorylated interleukin-3
 .and erythropoietin receptors, EMBO J. 14 1995 2816–
2826.
w x31 R.P. Piekorz, R. Blasius, G.H. Fey, G.M. Hocke, Kinetics of¨
the activation of the LIF-response factor in M1 myeloid
( )R.P. Piekorz et al.rBiochimica et Biophysica Acta 1402 1998 313–323 323
 .leukemic cells, Ann. New York Acad. Sci. 762 1995
452–454.
w x32 T. Naka, M. Narazaki, M. Hirata, T. Matsumoto, S. Mi-
namoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K.
Yoshizaki, S. Akira, T. Kishimoto, Structure and function of
 .a new Stat-induced Stat inhibitor, Nature 387 1997 924–
929.
w x33 R. Starr, T.A. Willson, E.M. Viney, L.J.L. Murray, J.R.
Rayner, B.J. Jenkins, T.J. Gonda, W.S. Alexander, D. Met-
calf, N.A. Nicola, D.J. Hilton, A family of cytokine-induci-
 .  .ble inhibitors of signalling, Nature London 387 1997
917–921.
w x34 T. Decker, P. Kovarik, A. Meinke, GAS elements: A few
nucleotides with a major impact on cytokine-induced gene
 .expression, J. Interferon Cytokine Res. 17 1997 121–134.
w x35 K.A. Lord, A. Abdollahi, B. Hoffman-Liebermann, D.A.
Liebermann, Proto-oncogenes of the fosr jun family of
transcription factors are positive regulators of myeloid dif-
 .ferentiation, Mol. Cell. Biol. 13 1993 841–851.
w x36 D. Wang, D. Stravopodis, S. Teglund, J. Kitazawa, J.N.
Ihle, Naturally occurring dominant negative variants of Stat5,
 .Mol. Cell. Biol. 16 1996 6141–6148.
w x37 A. Matsumoto, M. Masuhara, K. Mitsui, M. Yokouchi, M.
Ohtsubo, H. Misawa, A. Miyajima, A. Yoshimura, CIS, a
cytokine-inducible-SH2 protein, is a target of the JakrStat5
 .pathway and modulates Stat5 activation, Blood 89 1997
3148–3154.
w x38 K. Iwatsuki, T. Endo, H. Misawa, M. Yokouchi, A. Mat-
sumoto, M. Ohtsubo, K.J. Mori, A. Yoshimura, Stat5 activa-
tion correlates with erythropoietin receptor-mediated ery-
throid differentiation of an erythroleukemia cell line, J. Biol.
 .Chem. 272 1997 8149–8152.
w x39 A. Meinke, F. Barahmand-pour, S. Wohrl, D. Stoiber, T.¨
Decker, Activation of different Stat5 isoforms contributes to
cell-type-restricted signalling in response to interferons, Mol.
 .Cell. Biol. 16 1996 6937–6944.
w x40 I. Woldman, G. Mellitzer, M. Kieslinger, D. Buchhart, A.
Meinke, H. Beug, T. Decker, Stat5 involvement in the
differentiation response of primary chicken myeloid progen-
itor cells to chicken myelomonocytic growth factor, J. Im-
 .munol. 159 1997 877–886.
w x41 R.P. Piekorz, G.M. Hocke, Induction of differentiation by
IL-6-type cytokines is impaired in myeloid leukemia cells
 .unable to activate Stat5a, Cytokine 9 1997 639–649.
w x42 X. Liu, G.W. Robinson, K.-U. Wagner, L. Garrett, A.
Wynshaw-Boris, L. Henninghausen, Stat5a is mandatory for
adult mammary gland development and lactogenesis, Genes
 .Dev. 11 1997 179–186.
